Inadine® (povidone-iodine dressing) is a non-adherent antimicrobial wound dressing used for the prevention and management of infection in selected superficial wounds. It provides controlled antiseptic activity while helping protect the wound bed and minimize trauma during dressing changes.
Because iodine can be systemically absorbed, appropriate patient selection, wound assessment, and monitoring are important, particularly when Inadine is used for prolonged periods or over larger wound areas.
Inadine is a primary, non-adherent viscose dressing impregnated with a polyethylene glycol (PEG) base containing 10% povidone-iodine, equivalent to approximately 1% available iodine.
Povidone-iodine is a broad-spectrum topical antiseptic. When the dressing contacts the wound, available iodine is released from the povidone-iodine complex and provides antimicrobial activity at the wound surface.
The dressing is designed to:
A useful feature of Inadine is its color-change indicator. The dressing is initially orange-brown and becomes progressively lighter as the available iodine is depleted.
Inadine is most appropriate for superficial or shallow wounds, generally those measuring less than 1 cm in depth and without significant undermining, tunneling, or sinus formation.
Inadine may be considered for:
The decision to use an antimicrobial dressing should be based on a comprehensive wound assessment rather than wound appearance alone.
Inadine may be used when a wound demonstrates clinical features suggestive of local infection, including:
When infection is confined to the wound, topical antimicrobial management may be appropriate as part of the overall wound-care plan.
A topical dressing alone is not sufficient treatment for spreading or systemic infection.
When clinical findings suggest cellulitis, spreading infection, or systemic illness, the patient requires medical assessment. Inadine may be incorporated into local wound management while systemic antimicrobial therapy is provided when clinically indicated.
Signs requiring escalation may include rapidly expanding erythema, lymphangitis, fever, chills, increasing pain, systemic deterioration, or other evidence of invasive infection.
Inadine may also be considered prophylactically in selected patients whose wounds are considered at high risk of infection. Routine prolonged use of antimicrobial dressings on all clean wounds is generally unnecessary, and the indication should be reassessed regularly.
Inadine may be used in appropriately selected adult and pediatric patients, but special consideration is required because iodine can be absorbed systemically.
It should not be used in neonates or infants younger than 6 months, where iodine absorption may have a greater effect on thyroid function.
| Category | Clinical Considerations |
|---|---|
| Age | Avoid use in neonates and infants younger than 6 months because of the potential for systemic iodine absorption and effects on thyroid function. |
| Hypersensitivity | Do not use in patients with known sensitivity or allergy to iodine or other dressing components. |
| Wound Depth | Generally avoid in wounds deeper than 1 cm or wounds with significant undermining, tunneling, or sinus tracts. |
| Pregnancy & Breastfeeding | Avoid use during pregnancy and breastfeeding unless specifically directed by an appropriate clinician. |
| Dermatitis Herpetiformis | Avoid in patients with Duhring’s dermatitis herpetiformis. |
| Lithium Therapy | Notify the physician or nurse practitioner. Concurrent iodine exposure and lithium therapy may increase the risk of thyroid dysfunction, including hypothyroidism. Appropriate laboratory monitoring may be required. |
| Renal Impairment | Impaired renal function may increase the risk associated with systemic iodine accumulation, particularly with prolonged use or application to large wound areas. |
| Thyroid Disorders | Use cautiously in patients with thyroid disease. Thyroid-function monitoring may be appropriate when treatment is prolonged or involves large surface areas. |
Before applying Inadine, perform a comprehensive wound assessment that includes:
The continued need for an antimicrobial dressing should also be evaluated during subsequent dressing changes.
Select an Inadine dressing that is slightly larger than the wound bed.
Common dressing sizes include:
The dressing may be cut or folded as necessary to accommodate the wound. When cutting Inadine, it may be easier to cut the dressing while one or both backing papers remain attached.
Cleanse the wound and surrounding skin using sterile normal saline or an approved wound cleanser according to local policy.
Gently dry the periwound skin while avoiding unnecessary trauma to the wound bed. A skin-barrier product may be applied to the surrounding skin when appropriate, particularly when wound exudate or the selected secondary dressing creates a risk of periwound irritation or maceration.
Multiple layers of Inadine should generally be avoided. Layering the dressing may interfere with the movement of wound exudate into the secondary absorbent dressing. Retained moisture can subsequently contribute to periwound maceration.
The secondary dressing should therefore provide the appropriate level of absorption for the wound’s expected exudate volume.
Depending on the wound condition and amount of exudate, Inadine may remain in place for up to 7 days or may require replacement as frequently as twice daily.
Dressing-change frequency should be individualized according to:
One of the most clinically useful characteristics of Inadine is its visible color change:
Orange/brown → pale → white
As povidone-iodine is consumed, the dressing loses its characteristic orange-brown color and becomes progressively lighter.
When the dressing becomes white, the available iodine has largely been depleted and the dressing has lost its intended antiseptic activity. This provides a practical visual indication that dressing replacement should be considered.
If the primary dressing has become dry or difficult to remove, avoid forcibly pulling an adherent dressing from the wound bed. Wound-care principles favor minimizing mechanical trauma to newly formed or viable tissue.
Clinical signs and symptoms of local wound infection should improve, with an expected goal of resolution within approximately 14 days.
Failure to improve should prompt reassessment of:
When used prophylactically in appropriately selected high-risk wounds, the goal is to prevent the development of clinical wound infection.
Because Inadine is designed as a non-adherent dressing, removal should occur with minimal disruption to viable wound tissue, helping protect the wound bed during dressing changes.
Inadine is a povidone-iodine–impregnated, non-adherent antimicrobial dressing that can be useful for selected superficial wounds that are infected or at increased risk of infection. Its combination of topical antiseptic activity, low-adherence wound contact, and a visible iodine-depletion indicator makes it practical for many wound-care settings.
Successful use depends on appropriate wound selection, correct single-layer application, suitable secondary dressing selection, and regular reassessment. Particular caution is required in patients at increased risk from systemic iodine absorption, including those with thyroid or renal disease and those receiving lithium therapy.
Clinical Disclaimer: This article is intended for healthcare education and does not replace individualized clinical assessment, organizational wound-care protocols, or the manufacturer’s current instructions for use. Product indications, contraindications, and recommendations should be verified against current manufacturer and institutional guidance before clinical use.
